Thu.Oct 17, 2024

article thumbnail

3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev

Fierce Pharma

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.

FDA 312
article thumbnail

Should CVS Health Break Up?

MedCity News

CVS Health is reportedly exploring a breakup. But some experts aren’t sure if this is a good idea. The post Should CVS Health Break Up? appeared first on MedCity News.

Retail 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic

Fierce Pharma

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. | In a court decision filed in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s approval of MSN’s Entresto generic was unlawful. In issuing the decision, the judge upheld the green light that MSN won in July.

FDA 274
article thumbnail

Medicaid’s Health Equity Problem Starts and Ends with Health-Related Social Needs (HRSNs). Why Are They Being Overlooked?

MedCity News

While federal healthcare programs focus their attention on ensuring healthcare resources exist for communities in need, HRSNs become critical drivers of whether individuals can actually access and benefit from these resources. The post Medicaid’s Health Equity Problem Starts and Ends with Health-Related Social Needs (HRSNs). Why Are They Being Overlooked?

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

NIH study shows Bavarian Nordic's mpox shot elicits immune response in teens

Fierce Pharma

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, younger people have become markedly

225
225
article thumbnail

Wave sees RNA editing validation in early trial results

PharmaVoice

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

More Trending

article thumbnail

Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That

MedCity News

Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace The post Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That appeared first on MedCity News.

89
article thumbnail

Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny

Fierce Pharma

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. | Eli Lilly is making a series of investments in China. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Pharma 179
article thumbnail

NICE backs first targeted therapy for ALK+ lung cancer

pharmaphorum

NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients

article thumbnail

Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano

MedCity News

Sanofi’s equity investment in the new Orano Med entity comes a month after the pharmaceutical giant struck a €100 million deal to license a clinical-stage radiopharmaceutical developed for neuroendocrine tumors. Orano Med develops targeted cancer therapies based on lead-212, an alpha-emitting isotope. The post Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano appeared first on MedCity News.

Leads 69
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

First human skin atlas points way to healing without scars

pharmaphorum

The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing

91
article thumbnail

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Pharmaceutical Technology

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

article thumbnail

Sage cuts a third of its workforce after R&D setbacks

pharmaphorum

Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's

89
article thumbnail

Understanding AI-assisted patent drafting: What attorneys need to know

Clarivate

Artificial intelligence (AI) already enhances a range of legal processes. From contract and due diligence reviews to e-discovery and legal research, early adopters of AI have seen undeniable benefits in speed, accuracy and efficiency. Today, AI promises many of the same benefits in the context of patent preparation and prosecution. However, between the decision to invest in AI-assisted patent drafting software and achieving a positive return on investment, a lot of hype and mischaracterization c

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

Australia joins EU in turning down Alzheimer's drug Leqembi

pharmaphorum

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

74
article thumbnail

Vivan renews five-year lease at UK biotech hub White City Place

PharmaTimes

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma

Pharma 80
article thumbnail

op Pharma Marketing Trends Shaping the Future of Healthcare in 2025

Pharma Marketing Network

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. These trends are not only transforming how pharmaceutical companies engage with healthcare professionals and patients but also shaping the future of healthcare delivery. This article explores the top pharma marketing trends that are set to redefine the landscape in the coming years.

article thumbnail

New £4.5m initiative launched to address UK medicines manufacturing skills shortage

PharmaTimes

The two-year programme will use virtual reality technology to teach essential skills

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

The Power of Healthcare Branding: Strategies for Pharma Marketing Success in 2025

Pharma Marketing Network

In an increasingly competitive pharmaceutical landscape, the significance of healthcare branding has never been more pronounced. As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. This article delves into the essence of healthcare branding and explores strategic approaches for pharma marketing, emphasizing the importance of digital platforms and the measurement of bra

article thumbnail

Direct to Patient Healthcare

Healthcare Success

Struggling with burnout while maintaining high-quality healthcare services that patients love? Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. This podcast is a must-listen for healthcare leaders and primary care practitioners seeking innovative ways to enhance patient access, optimize care delivery, and address challen

article thumbnail

Sanofi, Orano Strike Deal to Develop Radioligand Medicines for Rare Cancers

PharmExec

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue.

article thumbnail

Alethea Instructor Assistant transforms how instructors manage reading assignments.

Clarivate

The Alethea Instructor Assistant is an AI-driven tool designed to streamline the creation of reading assignments for instructors. Guiding questions can boost student engagement with reading materials and foster critical thinking skills. Now available within Alethea , the Instructor Assistant enables educators to easily generate effective questions that bring reading assignments to life, seamlessly integrating into existing learning management system workflows.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Curzon Sponsors the 2024 AMBS Case Interview Competition

Curzon Consulting

17th October 2024 2 Minutes Curzon Consulting is thrilled to sponsor this year’s Alliance Manchester Business School Consultancy Case Competition. Introduced in 2016, the competition enables AMBS MBA students to showcase their skills, innovative thinking, and problem-solving abilities. It’s a platform that challenges them and provides them with real-world experience in tackling complex business scenarios in preparation for interview processes across a variety of industries.

article thumbnail

FDA Approves AbbVie’s Vyalev for Advanced Parkinson Disease

PharmExec

Vyalev is the first and only FDA-approved subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease.

FDA 52
article thumbnail

Sanofi collaboration to advance innovative radioligand therapies

European Pharmaceutical Review

Sanofi Orano Med (subsidiary of the Orano Group) have agreed a new collaboration to advance development of next-generation radioligand therapies for rare cancers. As part of the agreement, the two parties will invest in a new entity, valued at €1.9 billion. It will operate under Orano Med and focus on creating and trialling next-generation lead-212 ( 212 Pb) radioligand therapies.

Leads 52
article thumbnail

Increasing your likelihood of success in dealmaking discussions

Clarivate

In-licensing and acquisitions are fast tracks for pharmaceutical companies to access groundbreaking technologies and assets that will drive the next generation of transformative patient treatments. Dealmaking is not a trivial process. Audience members during the recent Clarivate webinar Emerging Deal Trends in Biotech and Pharma identified three of the biggest challenges they face when securing deals.

Pharma 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Navigating Social Media Regulatory and Ethical Standards

PharmExec

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member explains how pharmaceutical companies can effectively navigate the evolving regulatory landscape and ensure that their marketing activities comply with ethical standards and industry best practices.

Ethics 52
article thumbnail

Sage lays off 55% of R&D workforce and refocuses pipeline

Pharmaceutical Technology

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s cash runway.

59
article thumbnail

Findings from the NIAGRA Trial in Bladder Cancer and Mechanisms of Resistance

PharmExec

Shubh Goel, head, immune-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses findings from the NIAGRA trial regarding bladder cancer

52
article thumbnail

Glaukos eyes FDA approval for ocular therapy after Phase III win

Pharmaceutical Technology

The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.